Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
mi
from
Pinehurst, NC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Rhode Island Hospital Comprehensive Cancer Center
mi
from
Providence, RI
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Miriam Hospital
mi
from
Providence, RI
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Cancer Centers of the Carolinas - Easley
mi
from
Easley, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Cancer Centers of the Carolinas - Easley
mi
from
Easley, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Cancer Centers of the Carolinas - Grove Commons
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Cancer Centers of the Carolinas - Grove Commons
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Greenville Hospital Cancer Center
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Greenville Hospital Cancer Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
CCOP - Greenville
mi
from
Greenville, SC
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Union Hospital of Cecil County
mi
from
Elkton, MD
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated:  6/26/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Collection of Patient-Reported Symptoms and Performance Status Via the Internet
Status: Enrolling
Updated: 6/26/2017
Mountainview Medical
mi
from
Berlin Corners, VT
Click here to add this to my saved trials
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated:  6/26/2017
University of CA, Davis Cancer Center
mi
from
Sacramento, CA
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated: 6/26/2017
University of CA, Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Bellin Memorial Hospital
mi
from
Green Bay, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Bellin Memorial Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
St Vincent Regional Cancer Center
mi
from
Green Bay, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
St Vincent Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Mercy Health System Heme/Onc
mi
from
Janesville, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Mercy Health System Heme/Onc
mi
from
Janesville, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Oconomowoc Memorial Hospital
mi
from
Oconomowoc, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Waukesha Memorial Hospital
mi
from
Waukesha, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Waukesha Memorial Hospital
mi
from
Waukesha, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Riverview Hospital
mi
from
Wisconsin Rapids, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Riverview Hospital
mi
from
Wisconsin Rapids, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Marshfield Clinic
mi
from
Marshfield, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated:  7/12/2017
Gundersen Clinic, Ltd.
mi
from
La Crosse, WI
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy With Maintenance Lenalidomide and Rituximab in Relapsed/Refractory CLL/SLL
Status: Enrolling
Updated: 7/12/2017
Gundersen Clinic, Ltd.
mi
from
La Crosse, WI
Click here to add this to my saved trials
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  7/17/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 7/17/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
mi
from
Bethesda, MD
Click here to add this to my saved trials
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated:  7/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Status: Enrolling
Updated: 7/18/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated:  7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML
Status: Enrolling
Updated: 7/20/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
University of Florida
mi
from
Gainesville, FL
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
University Hospitals of Cleveland
mi
from
Cleveland, OH
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
Cleveland Clinic
mi
from
Cleveland, OH
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
The Mayo Clinic
mi
from
Rochester, MN
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated:  7/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Pilot Study to Assess the Feasibility of Collecting Quality of Life Data in Collaboration With the Stem Cell Therapeutic Outcomes Database
Status: Enrolling
Updated: 7/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/26/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)
Lenalidomide in Combination With Plerixafor in Patients With Previously Treated Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/26/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/1/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/1/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated:  8/1/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Study of Decitabine, Vorinostat, and Cytarabine in Acute Myeloid Leukemia
Status: Enrolling
Updated: 8/1/2017
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
Donor-Derived, CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Umbilical Cord Blood Transplantation
Status: Enrolling
Updated:  8/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Infusion of Allogeneic Umbilical Cord Blood-Derived Cluster of Differentiation Antigen 19 (CD19)-Specific T Cells
Donor-Derived, CD19-Specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies After Umbilical Cord Blood Transplantation
Status: Enrolling
Updated: 8/2/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Maryland
mi
from
Baltimore, MD
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials